Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation

Administration of the diuretic, spironolactone (SR), can inhibit chronic liver diseases. We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjecte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Toxicologic pathology 2018-07, Vol.46 (5), p.530-539
Hauptverfasser:	Murayama, Hirotada, Eguchi, Ayumi, Nakamura, Misato, Kawashima, Masahi, Nagahara, Rei, Mizukami, Sayaka, Kimura, Masayuki, Makino, Emi, Takahashi, Naofumi, Ohtsuka, Ryoichi, Koyanagi, Mihoko, Hayashi, Shim-mo, Maronpot, Robert R., Shibutani, Makoto, Yoshida, Toshinori
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Body Weight - drug effects Diet, High-Fat Drug Therapy, Combination Fatty Liver - complications Fatty Liver - drug therapy Fatty Liver - pathology Liver Neoplasms, Experimental - etiology Liver Neoplasms, Experimental - pathology Liver Neoplasms, Experimental - prevention & control Male NADPH Oxidases - metabolism Organ Size - drug effects Oxidative Stress - drug effects Precancerous Conditions - pathology Precancerous Conditions - prevention & control Quercetin - administration & dosage Quercetin - analogs & derivatives Quercetin - therapeutic use Rats, Inbred F344 Spironolactone - administration & dosage Spironolactone - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!